leisure time -WSS

leisure time

author：leisure time 2025-09-04 04:25:35 - browse：43

When is negative data positive enough? Who gets credit for scientific breakthroughs? And wasn’t biotech supposed to bounce back?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also discuss the latest news in the life sciences, including the FDA hearing on a BrainStorm Cell Therapeutics’ polarizing ALS treatment, the end of the road for a once-vaunted drug developer, and the sorry state of biotech stocks.

For more on what we cover, here’s the Mojsov story; here’s the latest on BrainStorm; here’s the news on Intercept Pharmaceuticals; here’s more on the biotech market; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

explore

leisure time

focus

WSS

Heat waves linked to early deliveries, preterm births in new study

Pharma patents targeted by Biden in move to slash drug prices

Addiction doctors spar with methadone clinics over legislation

Do more moles mean more problems? Not so, says new study

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Spinal cord stimulation reduces pain in amputees, study finds

focus

leisure time

explore

Jerome Adams on the need for new antivirals for Covid

What PEPFAR has meant on the ground in Ukraine

Affirmative action in medical school literally saved lives

Insmed lung disease drug hits target in key Phase 3 trial

Heart attack and stroke risk calculators need revising

CMS should re

Bright Health sells Medicare Advantage business to Molina

AI used to predict Covid

Peter Hotez and the public health issue of online harassment

CMS should re

hotspot

Roche to buy Carmot Therapeutics, developer of obesity drugs

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

FDA needs staff influx to meet gene therapy needs, Marks says

Startling documents reveal new facets of Sacklers' opioid empire

Scientists successfully use ultrasound imaging to map brain activity

leisure time

focus

focus

focus